NCT06831526 - Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2029

Study Completion Date

July 31, 2030

Conditions

Glioblastoma

Interventions

DRUG

Azeliragon

Provided by Cantex Pharmaceuticals

DRUG

Temozolomide

Standard of care.

RADIATION

Radiation therapy

Standard of care.

PROCEDURE

Surgery or LITT

Standard of care surgical resection or laser interstitial thermal therapy (LITT).

Trial Locations (1)

Washington University School of Medicine, St Louis